logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Tepotinib for advanced non-small cell lung cancer harbouring MET exon14- skipping mutations

< Back

Tepotinib for advanced non-small cell lung cancer harbouring MET exon14- skipping mutations

Drugs

Cancer and Palliative Care

January 2020


Tepotinib is in clinical development for patients with advanced non-small cell lung cancer (NSCLC) whose tumours have alterations in the MET gene. Advanced/metastatic (stage IV) NSCLC is when the cancer has spread to other organs most often to the liver, the adrenal glands, the bones and the brain. NSCLC is called locally advanced when it has spread into tissues around the lungs. Symptoms of NSCLC include fatigue, cough, shortness of breath, loss of appetite, coughing up phlegm, mucus or blood and chest pain. Most patients with metastatic NSCLC are diagnosed at the late stage where curative treatment with surgery is unsuitable. Currently, chemotherapy remains the main first line treatment option at this stage and is often not well tolerated by many patients.
Tepotinib is given as film coated tablets and it is a highly selective blocker of the protein c-MET which plays a key role in cell survival, growth and invasion. Tepotinib may help to induce death in tumour cells which overexpress c-MET. If licensed, tepotinib will offer an additional treatment option for patients with untreated stage IIIB/IV squamous or non-squamous NSCLC.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts